拉米夫定停药后肝炎的临床观察  

Clinical observations of lamivudine withdrawal hepatitis

作　　者：蔡皓东[1] 马秀云[1] 崔振宇[1] 

机构地区：[1]北京地坛医院,100011

出　　处：《肝脏》2002年第3期174-175,共2页Chinese Hepatology

摘　　要：目的　探讨拉米夫定停药后肝炎的发生率、临床特点、机制及防治。方法　对长期应用拉米夫定治疗后停药的患者进行 1年以上的随访。结果　拉米夫定停药后肝炎的总发生率为 13 .5 %。其发病原因是HBV复制失抑制后的再活动。已发生HBeAg/抗 HBe血清转换的患者停药后仍有可能发生拉米夫定停药后肝炎。 结论　对长期应用拉米夫定治疗的患者无论是否因发生血清转换而停药 ,都应继续监测肝功能。对发生停药后的肝炎患者 。Objective To appraise the frequency, clinical characteristics, mechanism and treatment of lamivudine withdrawal hepatitis. Methods The patients treated with lamivudine were followed up for over one year after its withdrawal.Results The total rate of lamivudine withdrawal hepatitis was 13.5%. The possible cause was loss of inhibition of replication of HBV which became reactivated. Even in those patients with serum conversion of HBeAg/anti HBe could also develop lamivudine withdrawal hepatitis. Conclusion In those patients receiving long term treatment of lamivudine, even if they had serum conversion of HBeAg/anti HBe when the drug is discontinued, their liver function should be monitored during follow up. In case with occurrence of lamivudine withdrawal hepatitis, lamivudine can be restarted or treated with glycyrrhizic preperations.

关 键 词：拉米夫定 停药后肝炎 血清转换 乙型肝炎病毒 发病率 临床特点 

分 类 号：R575.1[医药卫生—消化系统]